Medically reviewed by Regenerated Medical Advisory Board

Published November 17, 2025Updated June 25, 2026

TB-500 (Thymosin Beta-4): Healing, Recovery, and What the Research Shows

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide found in nearly every cell and tissue in the human body. Thymosin beta-4 plays a central role in tissue repair, cell migration, blood vessel formation, and inflammation control. TB-500 replicates the active region of this peptide, making it one of the most studied regenerative peptides for injury healing and recovery.

If you have heard of BPC-157, you have likely heard of TB-500 as well. The two peptides are frequently discussed together (and often stacked) because they promote healing through complementary mechanisms. But TB-500 has its own distinct research base and clinical profile that is worth understanding on its own terms.

At a Glance

TB-500 is a synthetic version of the active region (amino acids 17-23) of thymosin beta-4, a 43-amino-acid peptide naturally present throughout the body
It promotes healing by upregulating cell migration, reducing inflammation, promoting new blood vessel formation (angiogenesis), and modulating actin (a key structural protein in cells)
Research shows promise for muscle, tendon, and ligament injuries, cardiac repair after heart attack, wound healing, and hair regrowth
Commonly stacked with BPC-157 for enhanced tissue repair effects
Administered as subcutaneous or intramuscular injection, typically in a loading phase followed by a maintenance phase
Originally developed and widely used in veterinary medicine (equine injuries), now increasingly used in human clinical practice
Not FDA-approved for any human indication; regulatory status is evolving

What Is Thymosin Beta-4, and How Does TB-500 Relate to It?

Thymosin beta-4 (TB4) is a 43-amino-acid peptide that was first isolated from the thymus gland in the 1960s by Allan Goldstein at the Albert Einstein College of Medicine. Despite its name suggesting thymus-specific function, TB4 is actually found in virtually every tissue and cell type in the body. It is one of the most abundant intracellular peptides in human cells.¹

TB4’s primary intracellular function is regulating actin, the protein that forms the structural skeleton (cytoskeleton) of cells. Actin is essential for cell movement, cell division, and wound healing. When tissue is damaged, cells need to migrate to the injury site, and actin reorganization is what allows them to do that. TB4 is the master regulator of this process.

TB-500 is a synthetic peptide that corresponds to the active region of thymosin beta-4, specifically the amino acid sequence at positions 17 through 23. This short sequence (known as the actin-binding domain) is where most of TB4’s tissue repair activity is concentrated. By synthesizing just this active fragment, TB-500 delivers the healing properties of thymosin beta-4 in a form that is easier to manufacture and administer.²

Mechanisms of Action: How TB-500 Promotes Healing

TB-500 promotes tissue repair through several interconnected mechanisms. Understanding these helps explain why it has such broad applications across different types of injuries.

Cell Migration

When tissue is damaged, the body needs to move repair cells to the injury site. TB-500 promotes cell migration by interacting with actin, allowing cells to reorganize their internal structure and move directionally toward damaged areas. This effect is especially pronounced in endothelial cells (blood vessel lining), keratinocytes (skin cells), and various immune cells involved in wound repair.³

Angiogenesis (New Blood Vessel Formation)

Healing tissue needs blood supply. TB-500 strongly promotes angiogenesis, the formation of new blood vessels from existing ones. It does this by stimulating endothelial cell migration and proliferation. New blood vessel formation delivers oxygen and nutrients to the injury site, which is a rate-limiting step in tissue repair. This is one of TB-500’s most clinically significant effects.⁴

Anti-Inflammatory Effects

TB-500 reduces inflammation at injury sites through multiple pathways:

Downregulation of pro-inflammatory cytokines (IL-1beta, TNF-alpha)
Upregulation of anti-inflammatory mediators
Reduction of oxidative stress at the cellular level
Modulation of NF-kB signaling, one of the central inflammatory pathways

The anti-inflammatory effect is not as potent as corticosteroids (which suppress inflammation aggressively but also impair healing). TB-500’s anti-inflammatory action is more nuanced: it dials down excessive inflammation while preserving the inflammatory signals needed for proper tissue repair. This is an important distinction.⁵

Anti-Fibrotic Effects

Fibrosis (excessive scar tissue formation) is one of the main reasons injuries heal poorly. Scar tissue is structurally inferior to the original tissue. TB-500 has been shown to reduce fibrosis by modulating the balance between collagen deposition and degradation, favoring more organized, functional tissue repair rather than dense scar formation. This effect has been documented in cardiac tissue, liver, kidney, and skin models.

Research by Application

Muscle, Tendon, and Ligament Injuries

This is the most common clinical use of TB-500. The combination of cell migration, angiogenesis, and anti-inflammatory effects makes it particularly suited for musculoskeletal injuries. Research and clinical observations show:

Accelerated recovery from muscle strains and tears
Improved tendon healing with better structural organization
Reduced adhesion formation after tendon injuries
Faster return to function after ligament sprains

A study published in the Annals of the New York Academy of Sciences demonstrated that thymosin beta-4 promoted tendon repair in a rat model, with treated tendons showing improved tensile strength and reduced inflammation compared to untreated controls.⁶

Cardiac Repair

Some of the most compelling TB-500 research involves cardiac tissue. After a heart attack (myocardial infarction), the damaged heart muscle is replaced by scar tissue that cannot contract. This contributes to heart failure. Thymosin beta-4 has shown the ability to:

Reduce infarct size (the area of dead tissue) when administered after heart attack in animal models
Promote the migration of cardiac progenitor cells to the damaged area
Stimulate new blood vessel formation in the damaged heart tissue
Reduce cardiac fibrosis and improve cardiac function metrics

A landmark study by Bock-Marquette et al. published in Nature demonstrated that thymosin beta-4 promoted survival of cardiac muscle cells and improved cardiac function after myocardial infarction in mice. The peptide activated the pro-survival kinase Akt, protecting cardiomyocytes from cell death.⁷

Human cardiac trials are in early phases. RegeneRx Biopharmaceuticals has been developing RGN-352, a thymosin beta-4 formulation for cardiac repair, though clinical progress has been slower than initially anticipated.

Wound Healing

TB-500’s wound healing effects are well-documented in both animal models and clinical applications:

Accelerated closure of full-thickness skin wounds
Improved quality of healed tissue (less scarring, better organization)
Enhanced healing of diabetic wounds and ulcers (where healing is impaired)
Corneal wound healing (thymosin beta-4 eye drops have been studied for corneal injuries)

RegeneRx has also developed RGN-259, thymosin beta-4 eye drops for dry eye and corneal wound healing, which has progressed through multiple clinical trials with positive results.⁸

Hair Regrowth

Thymosin beta-4 has been shown to promote hair growth in animal models. The mechanism involves stimulation of hair follicle stem cells and increased blood vessel formation around hair follicles. In mouse studies, TB4 accelerated hair growth and increased hair follicle size. Whether this translates reliably to human hair regrowth is still under investigation, but some practitioners include TB-500 in hair restoration protocols, particularly in combination with other agents like GHK-Cu and PRP.⁹

TB-500 and BPC-157: The Stacking Protocol

TB-500 and BPC-157 are the two most commonly used healing peptides, and they are frequently combined (“stacked”) because they work through complementary mechanisms.

Feature	TB-500	BPC-157
Origin	Fragment of thymosin beta-4 (found throughout the body)	Derived from a protective protein in gastric juice (BPC = Body Protection Compound)
Primary mechanism	Actin regulation, cell migration, angiogenesis	Nitric oxide pathway modulation, growth factor upregulation, gut-brain axis effects
Strongest effects on	Muscle, tendon, cardiac tissue, blood vessel formation	GI tract, tendons, ligaments, nitric oxide-dependent healing
Anti-inflammatory profile	Moderate (cytokine modulation, NF-kB)	Strong (multiple inflammatory pathways, cytoprotective)
Systemic vs. local	Strong systemic effects	Both systemic and strong local effects when injected near injury
Angiogenesis	Strong promoter of new blood vessel formation	Moderate; promotes vessel formation through different pathways
Gut healing	Minimal direct gut effects	Strong gut healing and protection (its original discovery context)
Administration	SubQ or IM injection	SubQ, IM injection, or oral (for GI applications)
Research status	Extensive preclinical; limited human trials	Extensive preclinical; growing human clinical data

Common Stacking Protocol: TB-500 + BPC-157

Loading phase (2 to 4 weeks):

TB-500: 2.0 to 2.5 mg injected subcutaneously twice per week (total 4 to 5 mg/week)
BPC-157: 250 to 500 mcg injected subcutaneously once or twice daily (can be injected near the injury site)

Maintenance phase (4 to 8 weeks):

TB-500: 2.0 to 2.5 mg once per week
BPC-157: 250 mcg once daily or 500 mcg every other day

The rationale for stacking is that TB-500 provides strong systemic healing signals (cell migration, angiogenesis) while BPC-157 provides local tissue protection and additional growth factor stimulation. Together, they cover more healing pathways than either alone.

Dosing: Loading and Maintenance

TB-500 protocols typically use a two-phase approach:

Loading Phase (Weeks 1 to 4)

The loading phase uses higher doses to establish therapeutic tissue levels of the peptide. The standard loading protocol is 2.0 to 2.5 mg injected subcutaneously twice per week, for a total weekly dose of approximately 4 to 5 mg. Some aggressive protocols use up to 5 mg twice per week (10 mg total per week) for severe injuries, though this is less common.

Maintenance Phase (Weeks 5 to 12)

After the initial loading period, the dose is reduced to a maintenance level: 2.0 to 2.5 mg once per week or once every two weeks. The maintenance phase sustains the healing effects initiated during loading while reducing overall peptide exposure.

Injection Technique

Subcutaneous injection is the most common route (abdominal area, thigh, or near the injury site)
Some practitioners use intramuscular injection for muscle-specific injuries
TB-500 is systemic in its effects, so injection does not need to be directly at the injury site (though some practitioners prefer local injection for concentrated effects)
Reconstitute lyophilized TB-500 with bacteriostatic water according to pharmacy instructions
Store reconstituted peptide refrigerated (2 to 8 degrees C); use within 2 to 4 weeks of reconstitution

Veterinary Origins and Human Use

TB-500 has a long history in veterinary medicine, particularly in the horse racing industry. Equine athletes are prone to tendon, ligament, and muscle injuries, and TB-500 has been widely used to accelerate recovery in racehorses. This veterinary track record provided much of the early safety and efficacy data that later informed human clinical interest.¹⁰

The transition from veterinary to human use followed a familiar pattern in peptide medicine: practitioners observed the results in animals, reviewed the preclinical human cell and tissue studies, and began using it in clinical practice before formal human clinical trials were completed. This means that human use of TB-500 is based on a combination of strong preclinical evidence, veterinary experience, and growing clinical observation rather than large randomized controlled trials.

Safety and Side Effects

TB-500 has a generally favorable safety profile in both veterinary and human clinical use. Thymosin beta-4 is a naturally occurring molecule in the human body, which provides a baseline level of biological compatibility.

Reported side effects include:

Injection site reactions: Mild redness, swelling, or bruising at the injection site (common, temporary)
Headache: Occasionally reported, usually mild
Fatigue: Some users report temporary fatigue, particularly during the loading phase
Nausea: Rare, typically mild when it occurs
Lightheadedness: Occasionally reported after injection

Safety Considerations

Cancer concern: Because TB-500 promotes angiogenesis and cell migration, there is a theoretical concern that it could promote tumor growth or metastasis in patients with active cancer. Thymosin beta-4 levels have been found to be elevated in some tumor types. While there is no direct evidence that exogenous TB-500 causes cancer or accelerates cancer growth, patients with active malignancy or recent cancer history should avoid TB-500 until this question is better resolved.

Regulatory status: TB-500 is not FDA-approved for any human indication. It is available through compounding pharmacies and research peptide suppliers. The regulatory classification of peptides is evolving, and some peptides that were previously available through compounding have been restricted. Check current regulations with your prescribing provider.

Product quality: As with all peptides, sourcing matters. Use products from licensed compounding pharmacies that provide certificates of analysis showing purity (98% or higher) and sterility testing. Avoid purchasing from unregulated online suppliers without verification of quality control.

Pregnancy and breastfeeding: No safety data available. Avoid use during pregnancy and breastfeeding.

What to Expect: Timeline of Effects

Patients using TB-500 for injury recovery typically report the following timeline:

Week 1 to 2: Reduced pain and inflammation at the injury site. Some patients notice improved sleep quality.
Week 2 to 4: Noticeable improvement in range of motion, reduced stiffness, and early signs of functional recovery.
Week 4 to 8: Continued tissue remodeling and strength recovery. Most patients with moderate injuries report significant functional improvement by this point.
Week 8 to 12: Maintenance phase supports ongoing tissue remodeling. Full recovery timelines depend on injury severity and type.

Results vary considerably based on injury type, severity, patient age, and concurrent treatments (physical therapy, nutrition, other peptides). TB-500 is not a replacement for appropriate rehabilitation. It works best as an accelerant alongside standard recovery protocols.

References

Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta-4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. doi:10.1111/j.1749-6632.2010.05492.x
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta-4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. doi:10.1096/fj.03-0589fje
Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta-4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta-4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. doi:10.1096/fj.09-142307
Ehrlich HP, Hazard SW 3rd. Thymosin beta-4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. Ann N Y Acad Sci. 2010;1194:118-124. doi:10.1111/j.1749-6632.2010.05483.x
Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
Sosne G, Dunn SP, Kim C. Thymosin beta-4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. doi:10.1097/ICO.0000000000000379
Philp D, St-Surin S, Cha HJ, Moon HS, Kleinman HK, Elkin M. Thymosin beta-4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci. 2007;1112:95-103. doi:10.1196/annals.1415.009
Young JD, Lawrence AJ, MacLean AG, et al. Thymosin beta-4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med. 1999;5(12):1424-1427. doi:10.1038/71002

TB-500 (Thymosin Beta-4): Healing, Recovery, and What the Research Shows

TB-500 (Thymosin Beta-4): Healing, Recovery, and What the Research Shows

At a Glance

What Is Thymosin Beta-4, and How Does TB-500 Relate to It?